Director, Breast and Gynecologic Cancer Program
Sarah Cannon Research Institute/Tennessee Oncology
Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia, and received a NCAA Postgraduate Scholarship. She then completed her medical degree and residency from University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke’s Annual House staff Fellow Teaching Award. Dr. Hamilton is board-certified in both internal medicine and oncology
She joined Sarah Cannon Research Institute (SCRI) as investigator in drug development with a women’s cancer focus in 2013. In 2015, she became the director of the breast cancer research program and gynecologic cancer research program. She sees patients in both the phase I drug development unit and the standard of care clinic including phase II/ III clinical trials. She is also a partner within Tennessee Oncology.
Dr. Hamilton is the Chair of ASCO’s (American Society of Clinical Oncology) Scientific Committee for Metastatic Breast Cancer for 2019-2020 and has served on that committee as a member for the past 3 years. She also serves as an Associate Editor for Clinical Breast Cancer.
The Virginia Kerley Cade Endowed Chair in Developmental Therapeutics
Associate Director for Clinical Research, Stephenson Cancer Center
Associate Professor, Section of Gynecologic Oncology
Director, Gynecologic Oncology Fellowship Program
University of Oklahoma Health Sciences Center
Dr. Moore is the Virginia Kerley Cade Endowed Chair in Cancer Development and Associate Professor of Gynecologic Oncology in the Department of Obstetrics and Gynecology at the University of Oklahoma Health Sciences Center. She currently serves as the Associate Director of Clinical Research and the Director of the Oklahoma TSET Phase I Program at the Stephenson Cancer Center. She also serves as the Program Director of the Gynecologic Oncology Fellowship Program in the Section of Gynecologic Oncology of the Department of OB/GYN. She completed her gynecologic oncology fellowship at the University of Oklahoma Health Sciences Center in 2007 and was recruited to join the faculty. Her primary areas of interest are in new drug development and Phase I clinical trials.